Table 2.

Characteristics of patients with HCC

Number nodulesMaximum diameter, cmPortal vein thrombusExtrahepatic spreadBCLC stageSurveillance AFP levelSurveillance ultrasound results
13.2NoneNoA54.3
12.5NoneNoDa22.9+
12.5NoneNoA11.3+
73.2NoneNoB48.4Not done
11.4NoneNoA6.4Not done
11.8NoneNoDa3.8b
22.8BlandNoA2.3+
12.3NoneNoA73.0Not done
42.4BlandNoB25.8
21.1NoneNoA16.4Not done
13NoneNoDa13.6
12.2NoneNoDa27.7+
12.1NoneNoA37.8Not done
22.8NoneNoA23.5
22.3NoneNoA5.3+
23.8NoneNoB4.3+
11.5NoneNoDa42.2
12.8NoneNoA2.2+
32.2BlandNoA1,442.9+
213.7TumorYesC635Not done
12.1NoneNoA42.1Not done
13.2NoneNoA5.1+
12.0NoneNoA69.7Not done
11.7NoneNoA2.4b
23.2NoneNoB35.4+
34.2TumorYesC30.0
31.8NoneNoA33.2+
41.4NoneNoDa3.0+
12.1NoneNoA11.1
13.1NoneNoDa2.6b
23.6NoneNoB404.9+
12.6NoneNoA20.0+
21.4TumorYesC3.1+
13.2NoneNoA24.0+
24.6NoneNoB277.7Not done
20.6NoneNoDa2.2b
31.5NoneNoA15.7
22.0NoneNoA203.9
25.2NoneNoB36.8Not done
11.7NoneNoA10.1+
11.7NoneNoA3.2+

NOTE: Usual practice was to conduct triple-phase CT or MRI in patients with an increasing AFP level greater than 20 ng/mL.

  • aTumors were staged as BCLC D given underlying Child C cirrhosis at the time of diagnosis

  • bHCC was incidentally diagnosed at time of liver transplantation or when cross-sectional imaging was conducted to evaluate gastrointestinal symptoms (abdominal pain, nausea, and jaundice).